BVS
Bioventus Inc.
NASDAQ · Healthcare · Medical - Devices · US
$14.25
−0.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 581.8M | 568.1M | 573.3M | 512.3M | 512.1M |
| Cost of Revenue | 186.2M | 185.7M | 185.1M | 184.2M | 181.0M |
| Gross Profit | 395.6M | 382.4M | 388.2M | 328.2M | 331.1M |
| Operating Expenses | |||||
| R&D Expense | 11.6M | 12.1M | 13.6M | 13.4M | 23.9M |
| SG&A Expense | 321.6M | 311.8M | 327.1M | 303.9M | 332.1M |
| General & Admin Expense | — | — | 322.7M | 300.0M | 326.9M |
| Selling & Marketing Expense | — | — | 4.4M | 3.9M | 5.2M |
| Other Expenses | 626.0K | — | 59.5M | 92.6M | 142.3M |
| Total Operating Expenses | 333.8M | 323.9M | 400.2M | 409.9M | 498.3M |
| Cost and Expenses | 520.0M | 509.5M | 585.3M | 594.1M | 679.4M |
| Operating Income (EBIT) | 61.8M | 58.5M | (12.0M) | (81.7M) | (167.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 19.9M | 26.5M | 38.8M | 40.7M | 12.0M |
| Net Interest Income | (19.9M) | (26.5M) | (38.8M) | (40.7M) | (12.0M) |
| Other Non-Op Income/Expense | (23.2M) | (32.8M) | (37.1M) | (39.4M) | (21.8M) |
| Non-Operating Income (excl Interest) | 3.3M | 6.4M | (1.6M) | (1.3M) | 9.8M |
| EBT (Pre-Tax Income) | 38.6M | 25.7M | (49.1M) | (121.1M) | (189.0M) |
| Income Tax Expense | (22.8M) | (1.6M) | (5.3M) | 85.0K | (44.4M) |
| Bottom Line | |||||
| Net Income | 54.5M | 22.7M | (33.5M) | (156.2M) | (158.7M) |
| Earnings from Cont. Ops | 61.5M | 27.3M | (43.8M) | (121.2M) | (144.7M) |
| Earnings from Discont. Ops | — | — | — | (59.5M) | (54.8M) |
| Bottom Line Net Income | 54.5M | 22.7M | (33.5M) | (156.2M) | (158.7M) |
| Per Share | |||||
| Basic EPS | $0.80 | $0.34 | ($0.52) | ($2.49) | ($2.59) |
| Diluted EPS | $0.77 | $0.33 | ($0.52) | ($2.49) | ($2.59) |
| Revenue Per Share | $8.57 | $8.53 | $8.77 | $8.18 | $8.34 |
| Shares | |||||
| Basic Shares Outstanding | 67.9M | 66.6M | 65.4M | 62.6M | 61.4M |
| Diluted Shares Outstanding | 70.8M | 68.9M | 65.4M | 62.6M | 61.4M |
| Profitability Metrics | |||||
| EBITDA | 92.8M | 99.2M | 39.2M | (23.1M) | (121.6M) |
| D&A | 34.3M | 47.0M | 49.6M | 57.4M | 55.4M |
| EBIT | 58.5M | 52.2M | (10.3M) | (80.4M) | (177.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026